Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Feb 21, 2012 8:27pm
259 Views
Post# 19564235

RE: MGMT UPDATE. Q4 2012 for Steady State?

RE: MGMT UPDATE. Q4 2012 for Steady State?

Terry:

Excellent update on the continued transition for BRD. See also the comments alluded to Kerry Smith (notice any significant Haywood activity recently?) on the Mineweb article.

Of course the Yahoo brains trust do not understand (must be pretending for bash and buy reasons) the time that it takes to make these changes. e.g. What equipment "spread" was assumed in the NI 43-101? The recent update suggests the substitution of smaller (buckets) in order to reduce dilution. Reduce bucket size suggests more (haulage) cycles to to deliver the 800 tpd target.

Thus there trade-offs for every "optimization". The stopes inventory (target) seems extremely conservative; but I guess WD is still, "de-risking" the production. The question is how many stopes are in the present inventory and how long would it take to get to the 30.

In my experience, grades are assigned by round and mining activity (pilot, slash, backslash & bench,  see mining methods in OBSOLETE NI 43-101). In addition, a change from care and maintenance suggests a change in production personnel. Thus the timing of the personnel changes are interesting.

I welcome the focus on C147 by the interim CE. This will de-risk the mill feed.

BWDIK? This shows that WD is prepared to take the heat and delay the 25k Au OZ to 2013. However, once the geology team starts to fire on all cylinders, we may see an example of, "under promise and over deliver". Cause that is the ONLY remedy available to a CEO banished to the penalty box.

GLTAL-GLAP

Cheers

Stanley

 

 

 

Bullboard Posts